BlackRock Inc. raised its holdings in Luminex Corporation (NASDAQ:LMNX) by 14.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,776,500 shares of the medical instruments supplier’s stock after purchasing an additional 713,436 shares during the quarter. BlackRock Inc. owned 13.15% of Luminex Corporation worth $121,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in shares of Luminex Corporation by 2.6% during the 1st quarter. Bank of New York Mellon Corp now owns 660,135 shares of the medical instruments supplier’s stock worth $12,126,000 after acquiring an additional 16,562 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Luminex Corporation by 6.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,780 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 489 shares during the period. Karp Capital Management Corp bought a new position in shares of Luminex Corporation during the 1st quarter worth $225,000. Sei Investments Co. grew its stake in shares of Luminex Corporation by 10.9% during the 1st quarter. Sei Investments Co. now owns 5,946 shares of the medical instruments supplier’s stock worth $110,000 after acquiring an additional 582 shares during the period. Finally, Mason Street Advisors LLC grew its stake in shares of Luminex Corporation by 0.5% during the 1st quarter. Mason Street Advisors LLC now owns 8,713 shares of the medical instruments supplier’s stock worth $160,000 after acquiring an additional 46 shares during the period. Hedge funds and other institutional investors own 78.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Luminex Corporation (LMNX) Holdings Lifted by BlackRock Inc.” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/luminex-corporation-lmnx-holdings-lifted-by-blackrock-inc/1638039.html.

In other Luminex Corporation news, Director Robert J. Cresci sold 19,631 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total transaction of $372,596.38. Following the completion of the sale, the director now owns 260,358 shares of the company’s stock, valued at $4,941,594.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Shares of Luminex Corporation (NASDAQ:LMNX) opened at 20.31 on Wednesday. Luminex Corporation has a one year low of $17.64 and a one year high of $22.27. The stock has a market cap of $895.08 million, a PE ratio of 62.88 and a beta of 0.29. The company’s 50-day moving average price is $19.90 and its 200-day moving average price is $20.00.

Luminex Corporation (NASDAQ:LMNX) last released its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The business had revenue of $76.50 million during the quarter, compared to analyst estimates of $75.45 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. Luminex Corporation’s revenue for the quarter was up 19.2% on a year-over-year basis. Equities research analysts anticipate that Luminex Corporation will post $0.53 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 13th. Shareholders of record on Friday, September 22nd were issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 1.18%. The ex-dividend date of this dividend was Thursday, September 21st. Luminex Corporation’s dividend payout ratio is presently 75.00%.

LMNX has been the subject of several research reports. Zacks Investment Research downgraded Luminex Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. BidaskClub cut Luminex Corporation from a “hold” rating to a “sell” rating in a report on Friday, July 28th. ValuEngine cut Luminex Corporation from a “hold” rating to a “sell” rating in a report on Saturday, July 8th. Finally, TheStreet cut Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $20.00.

About Luminex Corporation

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Corporation (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.